Oral Ketamine
When ketamine is swallowed, first-pass metabolism produces high levels of norketamine — a different pharmacological footprint.
This page has been written and edited by the publisher. It has not been reviewed by a licensed clinician.
Profile
- Bioavailability: ~17% (extensive first-pass metabolism).
- Onset: 30–60 minutes.
- Duration: longer-acting, gentler peak.
- Metabolite profile: high norketamine relative to other routes.
Strengths
- Simple administration; no special equipment.
- Smoother experience curve, less acute dissociation.
- Useful in chronic pain and palliative contexts.
Trade-offs
- Smallest evidence base for depression-specific outcomes.
- Variable absorption with food and gut motility.
- Take-home supply requires the same safeguards as sublingual.
Publisher and editor of Ketalux, based in Chicago, Illinois. Ira is a ketamine therapy patient, not a clinician. This is editorial review, not medical review: Ira is not a licensed clinician and does not provide diagnosis or medical care. Ketalux does not accept compensation from providers in exchange for favorable editorial coverage, evidence ratings, recommendations, patient referrals, or organic provider ranking. Read the full publisher disclosure →
Educational use only. The content on this page is provided for general educational purposes and does not constitute medical advice, diagnosis, or treatment. Ketamine and related therapies carry risks and are appropriate only under qualified medical supervision. Always consult a licensed healthcare professional about your individual situation. Information may change as research evolves.

